Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Catholics and others around the world have been praying for the pope, a liberal reformer who has led the Church for almost 12 years.

The Vatican said the pope responded well to the treatment, with a good level of gas exchange, and remained conscious and alert at all times.

Evan Horowitz, executive director of the Center for State Policy Analysis at Tufts University, joins WBUR's Morning Edition to explain why neither utility companies' greed nor the market price for gas ...

Furs have been on every catwalk this season, and Etro sent out some of the best yet. The show opened with a shaggy, majestic ...

Colin Mochrie, former star of the improv comedy TV show 'Whose Line Is It Anyway?', joins WBUR's Morning Edition ahead of a Friday performance at the Wilbur Theatre.